Euractiv (Advocacy Lab)
EU Perspectives
European Biotechnology Magazine
APM Market Access
EU PERSPECTIVES - Six years after COVID-19 upended the world, governments are still struggling to agree on how future pandemics should be handled. But the World Health Assembly also revealed a broader shift: global health policy is no longer focused only on responding to crises, but increasingly on preventing them before they spiral out of control....
EU PERSPECTIVES - The latest hantavirus outbreak is forcing Europe to confront an uncomfortable reality: vaccines or treatments against some dangerous viruses may never reach the market. Not because the science is impossible, but because developing them is not commercially attractive for pharmaceutical companies. Brussels is increasingly...
EURACTIV - Benoît van den Hove tells Euractiv that scaling biotech companies at a global level still depends on capital that Europe does not yet mobilise at sufficient scale. Read more
APM MARKET ACCESS - The European Council and the European Parliament have reached a provisional agreement on implementing tariff elements of the EU-U.S. Joint Statement, as pharmaceutical industry groups warn that continued uncertainty around transatlantic trade could disrupt drug supply chains and increase pressure on smaller innovative companies....
